AJANTPHARM.NSE · Ajanta Pharma Limited

-

Please sign in to comment on AJANTPHARM.NSE

1 Comment

Admin

4 years, 2 months ago

Ajanta Pharma Limited is currently in a long term uptrend where the price is trading 23.0% above its 200 day moving average.

From a valuation standpoint, the stock is 12.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 5.4.

Ajanta Pharma Limited's total revenue rose by 15.0% to $7B since the same quarter in the previous year.

Its net income has increased by 64.2% to $2B since the same quarter in the previous year.

Finally, its free cash flow grew by 32.4% to $3B since the same quarter in the previous year.

Based on the above factors, Ajanta Pharma Limited gets an overall score of 4/5.

Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
Exchange	NSE
CurrencyCode	INR
ISIN	INE031B01049

PE Ratio	34.31
Target Price	2980
Dividend Yield	2.1%
Beta	0.24
Market Cap	315B

ABOUT

Ajanta Pharma Limited

Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.

AJANTPHARM.NSE · Ajanta Pharma Limited

-

Ajanta Pharma Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Ajanta Pharma Limited using a moving average strategy